Indication
In combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable (tumours ≥ 4 cm or node positive) non-small cell lung cancer in adults.
Medicine details
- Medicine name:
- nivolumab (Opdivo)
- SMC ID:
- SMC2619
- Pharmaceutical company
- Bristol-Myers Squibb Pharmaceuticals Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- 11 December 2023
- Patient group submission deadline:
- 02 October 2023